Medication-assisted treatment for alcohol use disorder is one of the most evidence-supported and least utilized tools in addiction medicine. The gap between what the research shows and how widely these treatments are actually used represents one of the most significant missed opportunities in addiction care today.
Part of the underutilization is stigma — the persistent belief that using medication to treat addiction is somehow a shortcut, a crutch, or evidence that someone isn’t truly committed to recovery. Part of it is lack of awareness — many people struggling with alcohol use disorder don’t know that FDA-approved medications exist that can significantly reduce cravings and support neurological stabilization in early sobriety. And part of it is a healthcare system that still under-trains providers in addiction medicine and under-refers patients to the treatments most likely to help them.
This blog is about what the evidence actually says — plainly, accurately, and without the mythology that has historically surrounded this topic.
What Is Medication-Assisted Treatment for Alcohol Use Disorder?
Medication-assisted treatment (MAT) for alcohol use disorder refers to the use of FDA-approved medications — in combination with therapy and behavioral support — to reduce cravings, decrease the rewarding effects of alcohol, and support the brain’s neurological recovery in early sobriety.
It’s important to be precise about what MAT is and isn’t. It is not a replacement for therapy, peer support, or the behavioral work of recovery. It is not a cure for alcohol use disorder. And it is not appropriate for everyone. What it is — for the right candidates — is a clinically meaningful tool that makes the other work of recovery more accessible by reducing the neurological pull of craving and the neurological chaos of early sobriety.
The three FDA-approved medications for alcohol use disorder are naltrexone, acamprosate, and disulfiram. Each works through a different mechanism, has a different evidence profile, and is appropriate for different clinical situations.
Naltrexone: Reducing the Reward
Naltrexone works by blocking opioid receptors in the brain — the same receptors through which alcohol produces much of its rewarding, pleasurable effect. When those receptors are blocked, alcohol simply doesn’t produce the same neurological reward it previously did. The reinforcement that drives continued drinking — the dopamine release, the sense of relief or pleasure — is significantly blunted.
The clinical evidence for naltrexone in alcohol use disorder is substantial. Multiple randomized controlled trials have demonstrated that naltrexone reduces both the frequency of heavy drinking days and the likelihood of returning to heavy drinking after a period of abstinence. It is available in both daily oral form and as an extended-release monthly injection — the injectable form offering the advantage of removing the daily decision to take the medication.
Naltrexone is most effective when combined with behavioral therapy and is generally well tolerated, with nausea being the most commonly reported side effect, typically resolving within the first few weeks. It is not appropriate for people currently using opioids or with acute liver disease.
Acamprosate: Supporting Neurological Stability
Acamprosate works through a different mechanism — targeting the glutamate system that is dysregulated during and after alcohol withdrawal. Chronic alcohol use suppresses glutamate activity; when alcohol is removed, glutamate rebounds to elevated levels, producing the hyperexcitability, anxiety, and craving that characterize early sobriety. Acamprosate helps normalize glutamate activity, reducing the neurological discomfort of early abstinence and the craving that drives relapse.
The evidence for acamprosate is strongest in people who have already achieved abstinence and are trying to maintain it — it appears to be particularly effective at reducing the anxiety and discomfort of protracted withdrawal that makes early sobriety so difficult for many people. It has a favorable side effect profile and is taken three times daily.
Acamprosate does not reduce the rewarding effects of alcohol the way naltrexone does — it works more by making sobriety feel more neurologically comfortable. For people whose primary struggle in early recovery is the persistent physical discomfort and anxiety of post-acute withdrawal, it can be a meaningful support.
Disulfiram: Aversion Through Consequence
Disulfiram works through a fundamentally different mechanism than naltrexone or acamprosate — rather than reducing cravings or normalizing brain chemistry, it creates a severe physiological reaction when alcohol is consumed. By blocking the enzyme that metabolizes acetaldehyde (a toxic byproduct of alcohol metabolism), disulfiram causes an intensely unpleasant reaction — flushing, nausea, vomiting, and rapid heart rate — when even small amounts of alcohol are consumed.
The evidence for disulfiram is more mixed than for the other two medications. Its effectiveness depends heavily on consistent adherence — a motivated patient who takes it reliably can find it a powerful deterrent; someone who stops taking it when they want to drink negates its effects. It is generally most appropriate for highly motivated individuals with strong external support structures, and requires careful medical oversight given the potential severity of alcohol-disulfiram reactions.
What the Evidence Says Overall
The body of evidence supporting MAT for alcohol use disorder is robust and consistent. Multiple systematic reviews and meta-analyses have found that both naltrexone and acamprosate significantly reduce drinking outcomes compared to placebo — and that MAT combined with behavioral treatment produces better outcomes than either approach alone.
Despite this evidence, MAT for alcohol use disorder remains dramatically underutilized. Studies suggest that fewer than 10% of people with alcohol use disorder who could benefit from these medications actually receive them. The reasons are complex — stigma, lack of provider training, patient reluctance — but the gap between evidence and practice represents a genuine public health problem.
At H.A.R.T. Recovery Care, MAT is evaluated as an option for every appropriate client. Our medical team reviews the evidence, assesses individual clinical factors, and has an honest conversation with each client about whether medication support is likely to be beneficial, what the options are, and what the evidence says about each. The decision to use MAT is always the client’s — but it’s a decision made with full clinical information, not in the absence of it.
MAT in the Context of In-Home Care
One of the practical advantages of H.A.R.T.’s in-home model is how naturally MAT integrates into ongoing care. Medication prescribing, monitoring, and adjustment happen within the same clinical relationship as therapy, peer support, and case management — not as a separate program requiring separate appointments with separate providers.
For clients using extended-release naltrexone injections, in-home administration by H.A.R.T.’s nursing staff removes even the logistical barrier of monthly clinic visits. For clients on daily oral medications, check-ins and adherence support are built into the regular cadence of care visits and virtual appointments.
This integration matters clinically. MAT is most effective when it’s part of a comprehensive care plan — not a standalone intervention — and H.A.R.T.’s model is specifically designed to deliver it that way.
Frequently Asked Questions
What medications are FDA-approved for alcohol use disorder? Three medications are currently FDA-approved for alcohol use disorder: naltrexone (available in oral and extended-release injectable forms), acamprosate, and disulfiram. Each works through a different mechanism and is appropriate for different clinical situations. H.A.R.T.’s medical team evaluates which option, if any, is most appropriate for each individual client.
Is medication-assisted treatment appropriate for everyone with alcohol use disorder? No — MAT is one tool among many, and its appropriateness depends on individual clinical factors including medical history, concurrent medications, motivation, and recovery goals. H.A.R.T.’s medical team evaluates MAT candidacy as part of the comprehensive clinical assessment and provides honest guidance about whether it’s likely to be beneficial.
Does using medication mean I’m not really in recovery? No. This is one of the most persistent and damaging myths in addiction treatment. Using FDA-approved, evidence-based medication to support neurological recovery from alcohol use disorder is not fundamentally different from using medication to manage any other chronic health condition. Recovery is defined by sustained wellness and meaningful engagement with life — not by the absence of medical support.
How long does medication-assisted treatment last? The duration of MAT varies by individual and by medication. Some people use MAT for several months during the highest-risk period of early recovery; others benefit from longer-term use. H.A.R.T.’s medical team makes individualized recommendations and monitors response over time, adjusting the plan as recovery progresses.
Can MAT be combined with therapy? Yes — and the evidence strongly supports combined treatment. MAT and behavioral therapy address different dimensions of alcohol use disorder and are most effective when used together. H.A.R.T.’s integrated care model delivers both within the same clinical relationship.
Evidence-Based Care, Delivered Personally
Medication-assisted treatment for alcohol use disorder is not a last resort, a shortcut, or a sign of insufficient commitment to recovery. It is a clinically validated, evidence-supported component of comprehensive addiction treatment — one that, for the right candidates, meaningfully improves outcomes.
At H.A.R.T. Recovery Care, we don’t let stigma or mythology drive clinical decisions. We let the evidence guide us — and then we deliver that evidence-based care in your home, with your comfort and dignity intact.
Call us at (559) 314-2148 or schedule a confidential consultation today. Evidence-based recovery starts with an honest conversation — and we’re ready to have it.
Medically Reviewed by Dr. Belis Aladag, MD, MPH, FASAM — Meet Dr. Aladag
H.A.R.T. Recovery Care serves clients in Fresno, Clovis, Visalia, Madera, Tulare, Porterville, and surrounding communities throughout California.